The NATALEE study evaluated the addition of 3 years of ribociclib to standard adjuvant ET in stage II and III breast cancer, including lymph node-negative patients (T2N0 with histological grade 3, grade 2 with Ki-67 > 20%, or high-risk genetic profiles). This evidence concerns the gene MKI67 and breast cancer.